tech.eu web signal

Boltz Raises $110M Series A Led by Bessemer for Drug-Design AI

TL;DR

  • Boltz raised a $110M Series A led by Bessemer, with Nvidia, Andreessen Horowitz and Greycroft joining, nearly four times its $28M January seed.
  • Six of the world's 20 largest pharma firms, including Pfizer, GSK, Takeda and Bristol Myers Squibb, are paying Boltz through a 'molecular tokens' API.
  • Paid token usage has grown roughly fiftyfold since the June launch of BoltzMol-1 for small molecules and BoltzProt-1 for protein design.

Boltz, the MIT spinout whose freely downloadable protein-structure models were already being compared to DeepMind's AlphaFold3, has closed a $110 million Series A led by Bessemer Venture Partners, tech.eu reported. The lab is headquartered in London's King's Cross with 40 AI researchers.

The round is nearly four times the $28 million seed Boltz raised earlier in the year. Existing backers Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures all came back in, and new investors Greycroft, F-Prime Capital, Hummingbird, Benchling and Nvidia joined.

The commercial pitch is the interesting part. In June, Boltz launched two paid proprietary models, BoltzMol-1 for small-molecule design and BoltzProt-1 for protein design, behind a consumption-priced API the company calls "molecular tokens." Paid token usage has grown roughly fiftyfold since that launch. Six of the world's 20 largest pharma companies are now customers, including Pfizer, GSK, Takeda and Bristol Myers Squibb, with DSM Firmenich also named on the platform.

Boltz's own numbers for what the paid models deliver: validated hit discovery "from months to weeks," at a cost "from hundreds of thousands of dollars to as low as $10,000." Those are company claims, not independently audited case studies.

CEO Gabriele Corso frames the destination as "a world where a scientist can go from a therapeutic hypothesis to a human-ready molecule without leaving their computer." The three co-founders, all from Regina Barzilay's lab at MIT CSAIL, released Boltz-1 as open source in November 2024; the open models have since accumulated "over 5 million downloads" among more than 100,000 scientists.

The cash goes to compute, data infrastructure and hiring. Boltz lands in a thickening cohort of structure-prediction labs chasing pharma discovery budgets, alongside Alphabet-backed Isomorphic Labs, reportedly in talks for a $5 billion round at a $50 billion valuation.